Organon to Acquire Dermavant including its Innovative …
WEB2 days ago · VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermatitis Proposed acquisition extends Organon’s international dermatology capabilities to the U.S. JERSEY CITY, N.J., September 18, 2024 – Organon (NYSE: OGN), a global healthcare company with a mission to improve ...
Dermavant Announces Positive Results from Phase 4 Open-Label Trial of VTAMA
WEBDec 6, 2023 · VTAMA cream reinforced strong efficacy for the treatment of head and neck plaque psoriasis (PsO), with 88.5% of adult patients (n=23/26) achieving a tPGA Success score of 0 (clear) or 1 (almost clear) and ≥2-grade improvement from baseline at Week 12, the primary endpoint of the study.
Organon to Acquire Dermavant including its Innovative …
WEB2 days ago · JERSEY CITY, N.J., September 18, 2024--Organon enters agreement to acquire Dermavant including innovative VTAMA (tapinarof) cream, 1%, a novel, non-steroidal topical dermatologic therapy.
Roivant sells dermatology spinoff to Organon in deal worth $1.2
WEB2 days ago · Roivant Sciences continues its dealmaking hot streak, announcing Wednesday that it would sell one of its subsidiaries to pharma company Organon in a deal worth $1.2 billion. Organon is buying ...
FDA Approves Dermavant’s VTAMA® (tapinarof) cream, 1% for
WEBMay 24, 2022 · As the first and only approved drug in its class in the U.S., the FDA’s approval of VTAMA cream provides an effective new non-steroidal treatment option for millions of adults living with plaque...
Organon pays up to $1.2B to acquire Dermavant and its steroid …
WEB3 days ago · Throughout the earnings period, Vtama steadily grew sales—from $13.7 million in the first quarter to $19.3 million in the fourth. As of May, 15,300 prescribers had written more than 385,000 ...
New Data from Phase 4 Trial of VTAMA® (tapinarof) Cream, 1
WEBOct 16, 2023 · On May 24, 2022, Dermavant announced the FDA approved VTAMA ® (tapinarof) cream, 1% for the treatment of adult plaque psoriasis. The approval made VTAMA cream the first non-steroidal topical novel chemical entity launched for psoriasis in the U.S. in more than 25 years.
FDA Approves Dermavant’s VTAMA® (tapinarof) cream, 1% for …
WEBMay 24, 2022 · FDA Approves Dermavant’s VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years.
Follow us on LinkedIn - Dermavant
WEBApr 29, 2024 · Dermavant has been developing VTAMA cream for the treatment of atopic dermatitis in adults and children 2 years of age and older and released positive topline results from its ADORING 1 and 2 pivotal Phase 3 clinical trials in 1H 2023.
VTAMA (Tapinarof) Cream, 1% Shows Efficacy in Patients With ...
WEBOct 20, 2023 · VTAMA (tapinarof) Cream, 1% performed well in intertriginous plaque psoriasis (iPsO), according to new Phase 4 data presented at the 43rd Annual Fall Clinical Dermatology Conference in Las Vegas. This Phase 4 study expands the body of data for VTAMA cream in adult plaque psoriasis.
Skip to content